Literature DB >> 24882839

Determinants of arterial stiffness in female patients with Takayasu arteritis.

Nilton Salles Rosa Neto1, Maurício Levy-Neto1, Elaine Cristina Tolezani1, Eloísa Bonfá1, Luiz Aparecido Bortolotto1, Rosa Maria Rodrigues Pereira2.   

Abstract

OBJECTIVE: The assessment of pulse wave velocity (PWV) in Takayasu arteritis (TA) is complex because of many confounding factors. We evaluated PWV in female patients with TA and controls with comparable anthropometric and clinical variables and assessed a possible association of TA with disease variables.
METHODS: We evaluated 27 patients with TA consecutively. Exclusion criteria were menopause, smoking, diabetes, renal insufficiency, poorly controlled hypertension, cardiac arrhythmias, obesity, inflammatory comorbidities, pregnancy, and surgical procedures involving the aorta. Disease activity was determined by clinical and laboratory variables. As healthy controls, 27 subjects with comparable age, blood pressure, height, and weight were selected. Carotid-femoral PWV measurements were obtained using the Complior system.
RESULTS: The mean PWV in patients with TA was higher than in healthy controls (9.77 ± 3.49 vs 7.83 ± 1.06 m/s; p = 0.009). Despite our strict selection criteria, patients with TA had an average systolic blood pressure (SBP) 8 mmHg higher than controls (p = NS), and significantly higher pulse pressure values. The multivariate linear regression model shows that 93.8% of the PWV variability is explained by the variables age, mean BP, and the disease itself (adjusted R(2) = 0.938). Stepwise logistic analysis using the PWV cutoff value established by the receiver-operator characteristic curve (> 8.34 m/s) as dependent variable, and measures with significance in univariate analysis as independent variables revealed that TA (OR 4.69; 95% CI 1.31-16.72; p = 0.017) and mean BP (OR 1.06; 95% CI 1.00-1.12; p = 0.048) were independently associated with higher PWV. Further analysis of disease variables revealed that PWV values were not correlated with erythrocyte sedimentation rate, C-reactive protein, cumulative dose of glucocorticoid, or ejection fraction (p > 0.05).
CONCLUSION: In our cohort of female patients with TA, the disease itself and mean BP were the strongest determinants associated with arterial stiffness.

Entities:  

Keywords:  ARTERIAL STIFFNESS; ATHEROSCLEROSIS; HYPERTENSION; PULSE WAVE VELOCITY; TAKAYASU ARTERITIS

Mesh:

Year:  2014        PMID: 24882839     DOI: 10.3899/jrheum.131110

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  5 in total

1.  Affected Microcirculation and Vascular Hemodynamics in Takayasu Arteritis.

Authors:  Christina Svensson; Niclas Bjarnegård; Per Eriksson; Hanna Jonasson; Tomas Strömberg; Christopher Sjöwall; Helene Zachrisson
Journal:  Front Physiol       Date:  2022-07-05       Impact factor: 4.755

2.  Arterial Stiffness and Adult Onset Vasculitis: A Systematic Review.

Authors:  Alberto Lo Gullo; Clemente Giuffrida; Carmela Morace; Giovanni Squadrito; Paola Magnano San Lio; Luisa Ricciardi; Carlo Salvarani; Giuseppe Mandraffino
Journal:  Front Med (Lausanne)       Date:  2022-05-12

3.  Pulse wave velocity, carotid intima media thickness and flow-mediated dilation in Takayasu arteritis: a systematic review.

Authors:  Jun Watanabe; Yoshitaka Iwazu; Kazuhiko Kotani
Journal:  Arch Med Sci Atheroscler Dis       Date:  2021-04-16

4.  Brachial-Ankle Pulse Wave Velocity is Increased and Associated with Disease Activity in Patients with Takayasu Arteritis.

Authors:  Zhiguang Wang; Aimin Dang; Naqiang Lv
Journal:  J Atheroscler Thromb       Date:  2019-07-04       Impact factor: 4.928

5.  Prognostic impacts of glucocorticoid treatment in patients with polymyalgia rheumatica and giant cell arteritis.

Authors:  Amir Emamifar; Torkell Ellingsen; Anne Pernille Hermann; Søren Hess; Oke Gerke; Ziba Ahangarani Farahani; Per Syrak Hansen; Inger Marie Jensen Hansen; Peter Thye-Rønn
Journal:  Sci Rep       Date:  2021-03-18       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.